• event

    New and Innovative Approaches to Laboratory Diagnosis of Zika, Dengue and other Arboviruses

May 2-4, 2017 - Les Pensières Center for Global Health, Veyrier du Lac, France

The aim of the Partnership for Dengue Control (PDC) is to cast a wider net to facilitate and expedite urgently needed technology development, both for research and to be rolled out in countries affected by arboviral diseases.

This workshop was organized, therefore, by the PDC and the Mérieux Foundations, with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur. Its purpose was to identify the gaps in the diagnosis of these viral infections, to review the new technological innovations that may be available to fill those gaps and to promote and develop mechanisms for accelerating the pathway from tool development to impact.

Critical need

The driving force behind the event was the critical need for more sensitive, specific and accurate diagnostic tests to support more effective surveillance and prevention and to halt the increased frequency and magnitude of epidemics and the higher incidence of severe disease outcomes caused by Zika, dengue and other arboviral infections.

Workshop outcomes

Key insights emerged to the 3 questions posed during the workshop:

Where are where are we now?

  • Diagnostic methods to detect DENV and ZIKV infections are still mainly laboratory-based and require further clinical evaluations,
  • Few validated assays are available on the market to differentiate ZIKV from other flavivirus infections,
  • Diagnostics that can be used at or near the point-of-patient care (POC) to detect and discriminate between the different flaviviral infections are needed.

Where do we go?

  • Towards specific molecular, serological, antigen-based and combination assays to identify and differentiate co-circulating flaviviral infections at or near POC, as well as for surveillance, in the intermediate and long-term future.

How do we make it happen?

  • Identify and address challenges: uncoordinated efforts, lack of funding mechanisms, limited access to well-characterized clinical samples, lack of definition of evaluation methods and sites, lack of regulatory harmonization, market opacity, low guarantee of return on investment (ROI), as well as slow and fragmented pathway to implementation,
  • Offer solutions: establish early partnerships and promote information sharing, facilitate access to samples and standardized protocols, promote regulatory harmonization, define priorities and build diagnostic preparedness strategies.

Workshop Report

Approximately 80 people attended the event including participants from academia, industry, NGOs, UN agencies (including WHO), investor organizations, policy makers and regulatory bodies. A full report has been published and includes a full list of participants and a summary of all the presentations, comments and strategies that resulted from the 3-day event.

Download full summary

Tuesday, May 2 – Day 1

Where are we now?

Session 1
Chairs: Annelies Wilder-Smith, Duane Gubler

  • Landscape analysis of the current status of Flavivirus diagnostics (dengue and Zika) – Maurine Murtagh, The Murtagh Group
    Download Presentation
Session 2
Chairs: Francis Moussy, Amy Lambert

  • Learning from successful novel technologies that made it to the market – Mark Miller, BioMerieux
    Download Presentation
  • Demand forecasting and market considerations – Nagwa Hasanin, UNICEF
    Download Presentation
  • Learning from past emergency authorizations – Elliot Cowan, Partners in Diagnostics
    Download Presentation

Wednesday, May 3 – Day 2

Where do we go? Technological innovations in Flavivirus diagnostics

Session 3: Detecting acute infection
Chairs: Maurine Murtagh, Arlene Chua

  • Imminent technological innovations
  • Cutting edge innovations for the intermediate and long-term future
  • Discussion
  • Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University
    Download Presentation
  • Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore
    Download Presentation
  • Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences
    Download Presentation
  • Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene
    Download Presentation
  • NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH
    Download Presentation
  • Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS
    Download Presentation
Session 4: Detecting past infections
Chairs: Eva Harris, Aravinda de Silva
Dx antigen discovery and imminent technological innovations

  • New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC
    Download Presentation
  • NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA
    Download Presentation
  • In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University
    Download Presentation
Cutting Edge Innovations For The Intermediate And Long-Term Future

  • VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux
    Download Presentation
  • A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA
    Download Presentation

Thursday, May 4 – Day 3

How do we make it happen? From idea to market

Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response
Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response

  • WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint
    Download Presentation
  • Diagnostics preparedness platform – Thomas Ullrich, Alere
    Download Presentation
  • Genetic analysis tool kit for rapid outbreak response – Michael Baffi, Thermo Fisher
    Download Presentation
Session 6: Critical steps to ensure quality products
Chairs: Rosanna Peeling, Piero Olliaro

Session 7: Identifying PDC’s roles to support innovative diagnostics
Chairs: May Chu, Julie Schäfer